Tasigna cleared for first-line CML use in Japan
This article was originally published in Scrip
Executive Summary
Japan's ministry of health, labour and welfare has confirmed the formal approval of Novartis' Tasigna (nilotinib) for first-line use in chronic myeloid leukaemia (CML), making it only the third such approval for the product worldwide.